Bicycle Therapeutics News and Activities

Bicycle Therapeutics is a company listed under the stock ticker BCYC (US).

View the org chart displaying its 28 main executives

Most searched biographies at Bicycle Therapeutics

• Kevin Lee, Chief Executive Officer and Director
• Jose-Carlos Gutierrez, Director
• Stephen Sands, Director

Popular executive movements at Bicycle Therapeutics

• Michael Skynner, who was Chief Technology Officer, is promoted to Chief Scientific Officer  (posted on February 3 2026).
• Michael Method, who was Senior Vice President, Clinical Development, is promoted to Chief Medical Officer  (posted on February 3 2026).
• Herve Hoppenot has joined the company as Director  (posted on September 9 2025).

Click here to view some more movements at Bicycle Therapeutics

Create your alert
to follow the executive moves at Bicycle Therapeutics.

Bicycle Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Bicycle Therapeutics

• Press Releases | Bicycle Therapeutics
• Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update | Bicycle Therapeutics
• Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry | Bicycle Therapeutics
• Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration | Bicycle Therapeutics
• Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression | Bicycle Therapeutics
• Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference | Bicycle Therapeutics
• Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting | Bicycle Therapeutics
• Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update | Bicycle Therapeutics
• Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting | Bicycle Therapeutics
• Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting | Bicycle Therapeutics
• View more press releases Close

Social media about Bicycle Therapeutics

• Bicycle Therapeutics on Wikipedia, Google News & Yahoo Finance
• Bicycle Therapeutics on LinkedIn, X (Twitter) & YouTube